Congress·In Committee·S. 932

Give Kids a Chance Act of 2025

Senate Committee Reviews Give Kids a Chance Act to Expand FDA Authority Over Pediatric Cancer Drug Studies

Mar 11, 2025·View on Congress.gov·Read full text

Part of: Congress Extends Rare Disease Vouchers and Boosts Pediatric Cancer Research

This bill is one vehicle in a longer effort. See the full story across every version.View effort →

StalledNext up: A senate committeeNo action in 16 months

A senate committee must act next: committee consideration.

Legislative Progress

Senate

No action since March 2025

House

President

Law

How we got here

This bill’s path across every version that has carried it.

Reintroduced
Reintroduced from H.R. 3433 (118th), which died when its Congress ended.
H.R. 3433 (118th) →

Key Points

Makes it easier for FDA to require drug companies to study some cancer drugs in kids, including certain drug combinations aimed at a specific tumor target.
Sets rules for those required kids’ studies so results are useful for real care, including the right medicine forms and dosing for different age groups.
Tells FDA to write and finalize public guidance on how to apply these new pediatric cancer study rules, on set timelines after the bill becomes law.
Delays when the new pediatric cancer study requirements would start: they apply to certain new drug applications filed 3 years after enactment.
Extends a program that rewards companies for developing treatments for rare pediatric diseases by keeping priority review vouchers available through Sept. 30, 2029, and orders government reports on how well the program works.

HealthcarePrescription Drugs

Impact Analysis

Personal Impact

How this policy affects specific groups of people

Mixed Impacts(1)

Federal Employee

Neutral

Positive Impacts(2)

Chronic Illness

Helps

Child Tax Credit

Helps

Milestones

2 milestones2 actions

Mar 11, 2025Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.

Mar 11, 2025

Introduced in Senate

The bill was officially filed and given a number. It now enters the legislative queue.

Related News

4 articles

The Ripon Advance·Dec 2, 2025

McCaul’s pediatric cancer bill passes House

The House unanimously passed the Mikaela Naylon Give Kids A Chance Act of 2025, which expands FDA authority to require pediatric research on drug combinations and reauthorizes the priority review voucher (PRV) program to spur development for rare childhood diseases.

Center Right

Pharmaceutical Technology·Dec 2, 2025

House passes bill that reauthorises the FDA’s paediatric priority voucher pathway

The Mikaela Naylon Give Kids a Chance Act combines initiatives to reauthorize the rare pediatric disease priority review voucher program and grant the FDA new authority to direct companies to study combinations of cancer drugs and therapies in pediatric trials.

Center

BioWorld·Dec 23, 2025

US Senate ends 2025 with no gift for kids with cancer

Despite unanimous House passage, the Mikaela Naylon Give Kids a Chance Act faced a year-end delay in the Senate due to objections over broader healthcare package costs, stalling the reauthorization of the critical priority review voucher program for rare pediatric diseases.

Center

No votes or related bills recorded for this bill yet.